Imc Chicago, LLC Bio N Tech Se Transaction History

Imc Chicago, LLC

$2.35 Billion
Q1 2025

A detailed history of Imc Chicago, LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Imc Chicago, LLC holds 31,508 shares of BNTX stock, worth $3.12 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

31,508

Previous 13,304 136.83%

Holding current value

$3.12 Million

Previous $1.52 Million 89.37%

% of portfolio

0.12%

Previous 0.05%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 14, 2025	BUY	$91.06 - $126.88 $1.66 Million - $2.31 Million	18,204 Added 136.83%	31,508 $2.87 Million
Q4 2024 Jan 27, 2025	SELL	$99.72 - $122.68 $1.91 Million - $2.35 Million	-19,132 Reduced 58.98%	13,304 $1.52 Million
Q3 2024 Oct 25, 2024	SELL	$78.36 - $124.66 $291,342 - $463,485	-3,718 Reduced 10.28%	32,436 $3.85 Million
Q2 2024 Jul 15, 2024	BUY	$80.36 - $102.87 $813,564 - $1.04 Million	10,124 Added 38.89%	36,154 $2.91 Million
Q1 2024 Apr 12, 2024	BUY	$88.96 - $112.35 $2.32 Million - $2.92 Million	26,030 New	26,030 $2.4 Million
Q2 2022 Aug 05, 2022	BUY	$123.25 - $186.24 $1.52 Million - $2.3 Million	12,360 Added 88.26%	26,364 $3.93 Million
Q1 2022 Apr 19, 2022	SELL	$126.25 - $231.85 $179,653 - $329,922	-1,423 Reduced 9.22%	14,004 $2.39 Million
Q4 2021 Feb 08, 2022	SELL	$216.64 - $362.52 $2.49 Million - $4.17 Million	-11,495 Reduced 42.7%	15,427 $3.98 Million
Q3 2021 Nov 05, 2021	BUY	$205.93 - $447.23 $5.54 Million - $12 Million	26,922 New	26,922 $7.35 Million

Others Institutions Holding BNTX

# of Institutions

340

Shares Held

40M

Call Options Held

1.43M

Put Options Held

1.54M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $24B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Imc Chicago, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Imc Chicago, LLC with notifications on news.

Account